Brokerages Anticipate BioLineRx Ltd. (NASDAQ:BLRX) to Post ($0.07) Earnings Per Share
Shares of BioLineRx Ltd. (NASDAQ:BLRX) have been assigned an average broker rating score of 2.00 (Buy) from the two brokers that cover the company, Zacks Investment Research reports. One research analyst has rated the stock with a hold rating and one has given a strong buy rating to the company. BioLineRx’s rating score has declined by 100% in the last three months as a result of a number of analysts’ upgrades and downgrades.
Brokerages have set a twelve-month consensus price target of $4.00 for the company and are expecting that the company will post ($0.07) earnings per share for the current quarter, according to Zacks. Zacks has also given BioLineRx an industry rank of 87 out of 265 based on the ratings given to its competitors.
A number of analysts have issued reports on BLRX shares. Roth Capital reaffirmed a “buy” rating and issued a $7.00 target price on shares of BioLineRx in a research note on Monday, September 26th. Maxim Group restated a “hold” rating and issued a $1.00 price objective on shares of BioLineRx in a report on Wednesday, September 7th. S&P Equity Research reduced their price objective on shares of BioLineRx from $1.24 to $1.10 in a report on Friday, September 23rd. Finally, Zacks Investment Research lowered shares of BioLineRx from a “buy” rating to a “hold” rating in a report on Tuesday, July 19th.
BioLineRx (NASDAQ:BLRX) opened at 1.06 on Wednesday. BioLineRx has a one year low of $0.71 and a one year high of $1.73. The firm has a 50-day moving average of $1.00 and a 200-day moving average of $0.93. The company’s market capitalization is $59.81 million.
BioLineRx (NASDAQ:BLRX) last issued its earnings results on Thursday, August 11th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.07) by $0.02. On average, analysts anticipate that BioLineRx will post ($0.26) earnings per share for the current year.
An institutional investor recently raised its position in BioLineRx stock. Menta Capital LLC boosted its stake in shares of BioLineRx Ltd. (NASDAQ:BLRX) by 11.7% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 98,917 shares of the company’s stock after buying an additional 10,400 shares during the period. Menta Capital LLC owned about 0.18% of BioLineRx worth $101,000 as of its most recent filing with the SEC. 12.46% of the stock is owned by institutional investors.
BioLineRx Company Profile
BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioLineRx Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.